WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have already received at least one ROS1 tyrosine kinase inhibitor.

The approval gives doctors another targeted treatment option for patients whose cancers are driven by ROS1 gene alterations, a relatively uncommon molecular subtype of non-small cell lung cancer.

The FDA approval is based on clinical trial evidence showing that Jideytro produced tumor responses in patients with previously treated ROS1-positive disease. Reuters reported that the drug demonstrated a 44% response rate among 117 patients in the data supporting the approval.

Jideytro is being developed by Nuvalent, which was acquired by GSK in a deal valued at approximately $10.6 billion. The approval therefore represents an important step for GSK as the pharmaceutical company expands its presence in oncology.

The treatment is designed to target ROS1-driven cancer while addressing an important challenge in lung cancer care: tumors can develop resistance after patients receive earlier targeted therapies.

The approval also comes as pharmaceutical companies increasingly focus on precision medicine, using genetic and molecular characteristics of tumors to identify treatments for specific patient groups rather than relying solely on broad cancer categories.

Jideytro will enter a competitive U.S. market that already includes other targeted therapies for ROS1-positive lung cancer. However, the FDA decision could give oncologists another option for patients whose disease has progressed following earlier ROS1-directed treatment.

For patients and the wider oncology community, the approval highlights the continued development of biomarker-driven cancer treatment in the United States.

As precision oncology expands, identifying specific genetic changes inside tumors is becoming increasingly important in determining which therapies may provide the best treatment opportunity.